I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| type II pneumocyte | 3 studies | 21% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| type II pneumocyte | 3 studies | 21% ± 3% |
Insufficient scRNA-seq data for expression of USP44 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 98% | 343.19 | 567 / 578 | 58% | 2.22 | 670 / 1155 |
| thymus | 100% | 215.11 | 652 / 653 | 41% | 0.87 | 247 / 605 |
| ovary | 99% | 179.59 | 179 / 180 | 37% | 1.06 | 159 / 430 |
| pancreas | 100% | 259.57 | 327 / 328 | 37% | 0.62 | 65 / 178 |
| uterus | 99% | 258.85 | 168 / 170 | 27% | 0.80 | 122 / 459 |
| bladder | 100% | 101.67 | 21 / 21 | 21% | 0.62 | 107 / 504 |
| kidney | 99% | 115.19 | 88 / 89 | 10% | 0.17 | 86 / 901 |
| adrenal gland | 95% | 110.09 | 245 / 258 | 13% | 0.25 | 29 / 230 |
| prostate | 97% | 140.98 | 237 / 245 | 8% | 0.10 | 40 / 502 |
| breast | 96% | 182.05 | 441 / 459 | 6% | 0.12 | 71 / 1118 |
| spleen | 100% | 185.97 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 2.39 | 1 / 1 |
| brain | 79% | 162.29 | 2083 / 2642 | 15% | 0.24 | 104 / 705 |
| esophagus | 83% | 177.67 | 1202 / 1445 | 9% | 0.17 | 17 / 183 |
| adipose | 92% | 141.83 | 1109 / 1204 | 0% | 0 | 0 / 0 |
| intestine | 87% | 172.38 | 842 / 966 | 3% | 0.09 | 18 / 527 |
| blood vessel | 82% | 87.41 | 1095 / 1335 | 0% | 0 | 0 / 0 |
| stomach | 62% | 92.62 | 224 / 359 | 4% | 0.08 | 12 / 286 |
| skin | 49% | 41.61 | 890 / 1809 | 5% | 0.11 | 25 / 472 |
| heart | 46% | 36.28 | 392 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 41% | 1.49 | 12 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 18% | 0.31 | 8 / 45 |
| muscle | 18% | 11.44 | 141 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 12% | 9.35 | 112 / 929 | 0% | 0 | 0 / 0 |
| liver | 1% | 0.49 | 2 / 226 | 5% | 0.12 | 22 / 406 |
| eye | 0% | 0 | 0 / 0 | 6% | 0.10 | 5 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0007059 | Biological process | chromosome segregation |
| GO_0006289 | Biological process | nucleotide-excision repair |
| GO_0051301 | Biological process | cell division |
| GO_0045066 | Biological process | regulatory T cell differentiation |
| GO_1904667 | Biological process | negative regulation of ubiquitin protein ligase activity |
| GO_0016579 | Biological process | protein deubiquitination |
| GO_0045841 | Biological process | negative regulation of mitotic metaphase/anaphase transition |
| GO_0090266 | Biological process | regulation of mitotic cell cycle spindle assembly checkpoint |
| GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
| GO_0140374 | Biological process | antiviral innate immune response |
| GO_0072686 | Cellular component | mitotic spindle |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0000785 | Cellular component | chromatin |
| GO_0005634 | Cellular component | nucleus |
| GO_0101005 | Molecular function | deubiquitinase activity |
| GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
| GO_0008270 | Molecular function | zinc ion binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | USP44 |
| Protein name | Ubiquitin specific peptidase 44 Ubiquitin carboxyl-terminal hydrolase 44 (EC 3.4.19.12) (Deubiquitinating enzyme 44) (Ubiquitin thioesterase 44) (Ubiquitin-specific-processing protease 44) ubiquitinyl hydrolase 1 (EC 3.4.19.12) |
| Synonyms | |
| Description | FUNCTION: Deubiquitinase that plays a key regulatory role in the spindle assembly checkpoint or mitotic checkpoint by preventing premature anaphase onset. Acts by specifically mediating deubiquitination of CDC20, a negative regulator of the anaphase promoting complex/cyclosome (APC/C) . Deubiquitination of CDC20 leads to stabilize the MAD2L1-CDC20-APC/C ternary complex (also named mitotic checkpoint complex), thereby preventing premature activation of the APC/C . Promotes association of MAD2L1 with CDC20 and reinforces the spindle assembly checkpoint . Promotes also the deubiquitination of histone H2A and H2B . Recruited to RNF8/RNF168-ubiquitinated chromatin surrounding double stranded breaks (DSBs), promotes hydrolysis of such ubiquitin conjugates, thus negatively regulating protein recruitment to damaged chromatin . Participates in nucleotide excision repair (NER) pathway by deubiquitinating DDB2 to prevent its premature degradation so it can remain on damaged chromatin (By similarity). Promotes FOXP3 stabilization through 'Lys-48'-linked deubiquitination leading to increased stability and increased regulatory T-cell lineage stability . Plays also a positive role in innate immune response to DNA viruses by deubiquitinating STING1, selectively removing its 'Lys-48'-linked polyubiquitin chains and stabilizing it . . |
| Accessions | ENST00000258499.8 F8VRW0 F8VRI7 ENST00000549639.1 ENST00000393091.6 ENST00000551837.1 Q9H0E7 ENST00000537435.2 F8VVD6 ENST00000552440.5 |
